Know when extended endocrine therapy is beneficial.
Avoid it when it isn't.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the ASCO® Clinical Practice Guideline now recognize Breast Cancer Index® (BCI) as the only genomic test that can predict the benefit of extended endocrine therapy in early-stage, HR+ breast cancer.1-2 That means avoiding potential overtreatment of patients for whom endocrine therapy beyond 5 years is unlikely to provide benefit.3-7 And informing treatment for the patients it may help.3-7
Cancer
Index
BCI CLINICAL EVIDENCE
The Predictive Power Of Breast Cancer Index
Breast Cancer Index Has Demonstrated Consistent Predictive Evidence Across 5 Studies and Over 4,500 Patients
Data supports comprehensive utility in pre- and post-menopausal women with various treatment histories and clinical features.
BCI CLINICAL EVIDENCE
Results from the Recent IDEAL Study
Results from the Recent IDEAL Study
The largest Breast Cancer Index validation expands on previous evidence, establishing the biomarker as being agnostic to TAM or AI treatment in women with HR+, early-stage breast cancer.
BCI CLINICAL EVIDENCE
BCI Predictive Validation: Trans-aTTom
Results from the Trans-aTTom Study
Trans-aTTom was the second prospective-retrospective study validating Breast Cancer Index prediction and established level 1B evidence for BCI as a biomarker for extended endocrine therapy response.
BCI CLINICAL EVIDENCE
Breast Cancer Index Prognostic Validation For Risk Of Late Distant Recurrence
Breast Cancer Index Has Extensive Validation Demonstrating Its Ability To Determine Risk Of Late (Post 5-Year) Distant Recurrence
The ability of Breast Cancer Index to determine an individual’s late distant recurrence has been validated across multiple studies, including various treatment histories, and a mix of pre- and post-menopausal patients.
OB/GYN RESOURCES
An OB/GYN's Perspective on BCI
OB/GYN's familiarity with adverse events from endocrine therapy gives patients an outlet
Watch Alison Cowan, MD, talk about the pivotal role OB/GYNs play in navigating treatment.
CLINICAL LANDSCAPE
Prognostic ≠ Predictive
BCI Is THE ONLY Commercially Available Test That Can Predict Whether Another 5 Years Of Endocrine Therapy Is Likely To Help Reduce Her Risk Of Late-Distant Recurrence
While clinicopathologic factors may help in the prognostic evaluation of recurrence risk, these factors and other commercially available tests have not been validated to predict benefit from extended endocrine therapy.
CLINICAL INSIGHTS
Breast Cancer Index
Predictive And Prognostic Information For Extended Endocrine Therapy Decision-Making
Breast Cancer Index (BCI) is THE ONLY commercially available test validated to inform the decision regarding extended endocrine therapy based on...
CLINICAL INSIGHTS
Ten Years Of Endocrine Therapy: Is It Right For Your Patients?
Nearly 95% Of Women With Early-Stage, Hormone Receptor–Positive (HR+) Breast Cancer Do Not Benefit From Extended Endocrine Therapy
Trials consistently demonstrate that only 3-5% of women benefit from extended endocrine therapy, supporting the strong need for individualized patient selection rather than broad use of prolonged treatment.
SIDE EFFECTS
Side Effects And Impact On Patient Quality Of Life Drives Noncompliance
In The Extended Endocrine Setting, Nearly 40% Of Patients Fail To Take Their Medication As Prescribed
In a Breast Cancer Index decision impact study, after receiving their results, 82% of patients that were recommended extended endocrine therapy reported they were more likely to be compliant with their treatment plan.
BCI CLINICAL EVIDENCE
Breast Cancer Index (BCI) Is Changing Physician Behavior
BCI results changed physician treatment recommendations in 30% of patients
In a prospective decision-impact study led by Yale University of 141 patients with early-stage, HR+ breast cancer on endocrine therapy for over 3.5 years, 30% of physician treatment recommendations regarding extended therapy changed after receiving a BCI result.
BCI CLINICAL EVIDENCE
Breast Cancer Index Is Transforming Clinical Assumptions
Looking Beyond Clinical Features Based On Individual Tumor Biology Can Impact Clinical Decision-Making
In a clinical study of 547 patients considered to be clinically low risk (T1N0), Breast Cancer Index identified ~25% as likely to benefit from extended endocrine therapy and high risk of late distant recurrence.
News & Insights
April 25, 2022
ASCO® Clinical Practice Guideline Now Includes Breast Cancer Index® to Guide Decisions about Extended Endocrine Therapy
Hologic, Inc. announced today that the ASCO® Clinical Practice Guideline has published an update which expands the utility of Breast Cancer Index® (BCI) within its Clinical Practice Guideline: “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.”
Read moreDecember 17, 2020
Breast Cancer Index® demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9th at this years’ San Antonio Breast Cancer...
Read moreDecember 08, 2020
Biotheranostics to premiere new data on Breast Cancer Index® and prediction of endocrine therapy benefit at SABCS 2020
New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held virtually from December 8-12, 2020. Breast Cancer Index continues to expand on a strong body of evidence as the only commercially ...
Read moreOctober 29, 2020
Biotheranostics' Breast Cancer Index® IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors.
Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast Cancer Index (BCI) and predictive evidence in patients treated with aromatase inhibitors. In collaboration with Leiden University...
Read moreNot Another Minute Prescribing Treatment That May Not Benefit Her
It is important to determine whether the treatment is likely to reduce her risk of recurrence before exposing her to potential risks associated with extended treatment. In the ATLAS Trial2 (extended TAM) 16 recurrences were prevented...
Read moreReferences: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed February 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F et al. J Clin Oncol. Published online April 19, 2022. DOI: 10.1200/JCO.22.00069. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org]. ASCO makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way. 3. Davies C, et al. Lancet. 2013;381:805-816. 4. Gray R, et al. J Clin Oncol. 2013;31:(suppl; abstr 5). 5. Jakesz R, et al. J Natl Cancer Inst. 2007;99:1845-1853. 6. Goss PE, et al. J Natl Cancer Inst. 2005;97:1262-1271. 7. Mamounas EP, et al. NSABP B-42. GS4-01. SABCS 2019. 8. Goss PE, et al. N Engl J Med. 2016;375:209-219.
Back to Top
